Introduction

Earlier this year, a supply disruption shook the UK’s orthopaedic community, hitting something many might overlook: bone cement. This vital material plays a key role in knee surgery and other joint procedures, especially for trauma patients and those facing certain cancer treatments. When the main bone cement supplier, Heraeus Medical, paused production due to a packaging fault, clinicians and patients alike faced new challenges.

In this article, we’ll unpack the impact of the bone cement shortage, explore how clinical practices have adapted, and explain how some clinics, like ours, have managed to keep patient care on track despite the hurdles.

Why Bone Cement Matters in Knee Surgery

Bone cement is the "glue" that holds many types of knee implants firmly in place. It provides stability and support, making a big difference to how well a knee replacement functions over time. It’s especially important in trauma cases—think fractured hips—and in certain cancer surgeries where prosthetic parts need a strong, secure fit.

Most patients who need cemented implants are those with weaker bones or tricky surgical situations. Brands like Heraeus Palacos and Copal are widely trusted because they include antibiotics that help reduce infections post-surgery. For many clinicians, bone cement remains the go-to choice because solid evidence shows it offers dependable results in complex or urgent cases.

What Happened: The Bone Cement Shortage in the UK

The problem started when Heraeus Medical discovered a fault in their packaging that could affect the sterility of their bone cement products. Since Heraeus supplies around 80% of the UK’s bone cement, this was a big deal. Key products like Palacos R+G suddenly vanished from the supply chain.

Hospitals realised they had only about two weeks' worth of stock left at normal usage rates, putting thousands of planned operations at risk of delay. The NHS and professional bodies quickly stepped in. Groups including the British Orthopaedic Association and the British Association for Surgery of the Knee issued guidance to prioritise urgent cases: trauma fractures needing speedy surgery, cancer-related replacements, and infected joint revisions.

For routine and elective procedures, they advised clinics to postpone surgeries or consider uncemented implants where possible. This triage aimed to balance patient safety with fairness across the system, while encouraging hospitals to explore alternative suppliers, though these came with their own challenges.

How Our Klinik Navigated the Crisis

At our Klinik, we were fortunate that the shortage had little direct impact on our knee patients. That’s because, for many years, we have favoured uncemented knee implants where appropriate. These implants don’t rely on bone cement for fixation but instead encourage the patient’s own bone to grow into the implant, securing it naturally.

This approach suits patients with good bone quality and has a solid evidence base supporting its effectiveness. In the face of the supply shortage, continuing with this pathway allowed us to avoid delays and maintain safe, high-quality care for most primary knee replacements.

We ensured every patient was fully informed about their implant choices, matching national guidance for clear communication and consent. While this method isn’t suitable for every case — especially urgent trauma or cancer patients — it proved a valuable alternative that kept our services running smoothly during a difficult period.

Leadership and Teamwork: Key to Managing Change

One major factor behind our successful adaptation has been strong leadership. Professor Paul Lee, a recognised orthopaedic surgeon and regional leader, has played a vital role in steering clinical teams through this challenging time. With advisory roles at the Royal College of Surgeons of Edinburgh and a wealth of surgical experience, his guidance has helped ensure clinical decision-making remained patient-centred and evidence-driven.

The broader MSK Doctors team at our Klinik fosters a supportive and professional atmosphere, encouraging multidisciplinary cooperation. This culture allows us to swiftly update protocols, train staff on alternative implants, and develop personalised care plans.

We don’t claim to have invented new solutions, but creating a flexible and well-led environment has been crucial in delivering uninterrupted care, despite national supply issues.

Looking Ahead: What Has Changed and What Remains

The bone cement shortage has been a wake-up call about the fragility of supply chains in healthcare and the need to stay agile. We’ve seen shifts in clinical guidelines and a renewed focus on prioritising urgent cases.

But some things remain constant: the dedication to patient safety, transparency, and using evidence to guide treatment choices. Our experience highlights how alternative strategies—such as using uncemented implants—can offer resilience when materials are scarce.

With ongoing leadership, collaboration across the orthopaedic community, and innovation in care pathways, the future remains optimistic. Knee patients across the UK can be reassured that experts are working hard to keep delivering safe, effective surgery—even in the face of unexpected challenges.

If you’d like, we can also provide a simpler summary for patients or discuss how these changes might affect your care options. Just get in touch.